Your browser is no longer supported. Please, upgrade your browser.
SGMO Sangamo Therapeutics, Inc. daily Stock Chart
SGMO [NASD]
Sangamo Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own0.10% Shs Outstand118.25M Perf Week-27.02%
Market Cap1.01B Forward P/E- EPS next Y-1.29 Insider Trans0.00% Shs Float115.40M Perf Month-12.18%
Income-118.40M PEG- EPS next Q-0.33 Inst Own72.40% Short Float14.79% Perf Quarter-24.69%
Sales74.40M P/S13.53 EPS this Y-0.90% Inst Trans2.90% Short Ratio12.12 Perf Half Y-12.81%
Book/sh3.62 P/B2.35 EPS next Y-4.90% ROA-19.40% Target Price20.67 Perf Year-26.45%
Cash/sh3.00 P/C2.84 EPS next 5Y- ROE-30.40% 52W Range6.26 - 13.91 Perf YTD-25.87%
Dividend- P/FCF- EPS past 5Y-8.20% ROI-21.10% 52W High-38.82% Beta2.87
Dividend %- Quick Ratio4.80 Sales past 5Y28.50% Gross Margin- 52W Low35.94% ATR0.63
Employees302 Current Ratio4.80 Sales Q/Q-6.80% Oper. Margin- RSI (14)35.04 Volatility10.62% 5.62%
OptionableYes Debt/Eq0.00 EPS Q/Q-86.90% Profit Margin- Rel Volume1.38 Prev Close8.68
ShortableYes LT Debt/Eq0.00 EarningsNov 06 AMC Payout- Avg Volume1.41M Price8.51
Recom2.20 SMA20-16.19% SMA50-9.35% SMA200-18.08% Volume1,936,782 Change-1.96%
Aug-26-19Initiated H.C. Wainwright Buy $16
Nov-14-18Downgrade JP Morgan Overweight → Neutral
Nov-09-18Downgrade Guggenheim Buy → Neutral
Oct-10-18Initiated Guggenheim Buy
Jun-20-18Initiated BofA/Merrill Buy $24
Nov-15-17Upgrade Piper Jaffray Neutral → Overweight
Jun-22-17Resumed Jefferies Buy $17
Nov-01-16Downgrade Wedbush Outperform → Neutral $30 → $4
Oct-19-16Downgrade Piper Jaffray Overweight → Neutral
Dec-04-15Initiated Wells Fargo Outperform
Oct-23-15Resumed Jefferies Buy
May-03-13Initiated BioLogic Equity Research Sell
Feb-23-11Reiterated JMP Securities Mkt Outperform $9 → $12
Jul-29-10Reiterated Wedbush Outperform $12 → $13
Oct-19-09Initiated Brean Murray Sell $4
Oct-07-09Reiterated Leerink Swann Outperform $9 → $11
Aug-25-09Reiterated JMP Securities Mkt Outperform $13 → $15
Apr-14-09Downgrade Cantor Fitzgerald Buy → Hold
Feb-23-09Reiterated Leerink Swann Outperform $6 → $9
Feb-05-09Upgrade Merriman Curhan Ford Neutral → Buy
Dec-12-19 07:37PM  Hedge Funds Are Dumping Sangamo Therapeutics, Inc. (SGMO) Insider Monkey
Dec-09-19 06:45AM  Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia Business Wire -11.58%
Dec-07-19 09:00AM  Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment Business Wire
Dec-06-19 09:33AM  The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics Zacks
08:30AM  Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day Business Wire
Dec-05-19 10:12AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
Dec-04-19 09:29AM  Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session Zacks
Dec-03-19 11:53AM  The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga +6.36%
Nov-26-19 08:30AM  Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors Business Wire
Nov-22-19 10:29AM  BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A Zacks
10:16AM  Investors Hope for More From Takeda Than a Healthy Dividend GuruFocus.com
Nov-19-19 10:08AM  We're Keeping An Eye On Sangamo Therapeutics's (NASDAQ:SGMO) Cash Burn Rate Simply Wall St.
07:00AM  Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation Business Wire
Nov-18-19 04:05PM  Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference Business Wire
Nov-14-19 10:59AM  Edited Transcript of SGMO earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-08-19 08:30AM  Sangamo Therapeutics Announces New Scientific Advisory Board Business Wire +5.46%
Nov-06-19 05:15PM  Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Sangamo Therapeutics Reports Third Quarter 2019 Financial Results Business Wire
09:00AM  Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting Business Wire
Nov-01-19 08:01AM  Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer Business Wire
Oct-30-19 04:15PM  Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast Business Wire
Oct-28-19 08:15PM  Is Sangamo Therapeutics, Inc. (SGMO) Going to Burn These Hedge Funds? Insider Monkey
Oct-01-19 01:01PM  What Kind Of Shareholder Owns Most Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stock? Simply Wall St.
Sep-30-19 04:15PM  Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer Business Wire
08:30AM  Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Aug-30-19 08:30AM  Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Aug-17-19 08:00AM  Does Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Salary Reflect Performance? Simply Wall St.
Aug-14-19 09:02PM  Edited Transcript of SGMO earnings conference call or presentation 7-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-09-19 07:18AM  Sangamo Biosciences Inc (SGMO) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 06:00AM  What You'll Want to Know About Sangamo Therapeutics' Q2 Results Motley Fool
Aug-07-19 06:05PM  Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  Sangamo Therapeutics Reports Second Quarter 2019 Financial Results Business Wire
Aug-06-19 04:05PM  Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire +5.15%
Aug-02-19 10:52AM  BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss Zacks
Jul-31-19 04:15PM  Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel Business Wire
04:05PM  Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast Business Wire
Jul-29-19 11:00AM  Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases Business Wire
Jul-12-19 02:25PM  Shake-Up in Big Weed Motley Fool
Jul-11-19 09:02AM  Here's Why Sangamo Therapeutics Jumped 23% in June Motley Fool
05:33AM  Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised) Zacks
Jul-09-19 11:10AM  A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019 Benzinga
11:07AM  Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study Zacks
10:40AM  BioMarin (BMRN) to File for Hemophilia A Candidate in Q4 Zacks
Jul-08-19 05:05PM  What Happened in the Stock Market Today Motley Fool
04:18PM  Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals Investor's Business Daily
03:31PM  Sangamo Therapeutics News: SGMO Stock Surges on Gene Therapy Study InvestorPlace
01:50PM  A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019 Benzinga
12:58PM  Here's Why Sangamo Therapeutics Is Surging Today Motley Fool
07:10AM  Sangamo Shares Soar as Hemophilia Drug Shows Promise TheStreet.com
Jul-05-19 11:15PM  Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels Business Wire
08:55AM  The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight Benzinga
Jul-02-19 08:39AM  Implied Volatility Surging for Sangamo (SGMO) Stock Options Zacks +5.48%
Jul-01-19 01:10PM  American Gene Technologies: The Software Revolution for the Next 100 Years Zacks Small Cap Research
11:00AM  Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntingtons Disease Business Wire
Jun-29-19 08:25AM  The Week Ahead In Biotech: Pending Clinical Readouts In Focus Benzinga
Jun-21-19 09:16AM  Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire
Jun-19-19 09:32PM  Heres What Hedge Funds Think About Sangamo Therapeutics, Inc. (SGMO) Insider Monkey
Jun-12-19 09:35PM  Edited Transcript of SGMO earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents
10:30AM  Denali's Hunter Syndrome Candidate Gets Orphan Drug Status Zacks
May-28-19 05:35PM  A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last? American City Business Journals
May-15-19 04:30PM  Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences PR Newswire
May-10-19 08:30AM  Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference PR Newswire
May-09-19 01:23PM  Sangamo Biosciences Inc (SGMO) Q1 2019 Earnings Call Transcript Motley Fool -14.77%
11:21AM  Here's Why Sangamo Therapeutics Fell as Much as 13.6% Today Motley Fool
May-08-19 10:15PM  What You Need to Know About Sangamo Therapeutics' Q1 Earnings Results Motley Fool
06:15PM  Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:01PM  Sangamo: 1Q Earnings Snapshot Associated Press
04:01PM  Sangamo Therapeutics Reports First Quarter 2019 Financial Results PR Newswire
03:00PM  Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-05-19 09:10AM  If You Had Bought Sangamo Therapeutics (NASDAQ:SGMO) Stock Three Years Ago, You Could Pocket A 93% Gain Today Simply Wall St.
May-02-19 02:56PM  Heres What Hedge Funds Think About Sangamo Therapeutics, Inc. (SGMO) Insider Monkey
May-01-19 04:01PM  Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast PR Newswire
Apr-28-19 11:52PM  Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock? Zacks
Apr-15-19 04:01PM  Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy PR Newswire
Apr-08-19 04:01PM  Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
Apr-05-19 06:00AM  Sangamo- Biotech "Fires on All Cylinders" MoneyShow
Apr-04-19 08:00AM  Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire -6.83%
07:58AM  The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut Benzinga
Apr-03-19 04:01PM  Sangamo Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire +6.02%
10:15AM  Sangamo Rises on Positive Phase I/II Hemophilia Study Data Zacks
09:15AM  Stocks Hold Onto Gains in Quiet Session Zacks
08:13AM  Does Sangamo Have the Best Gene Therapy Program Now? Motley Fool
07:37AM  3 Big Stock Charts for Wednesday: Twitter, Western Union and Wynn Resorts InvestorPlace
Apr-02-19 04:30PM  Why Delta Air Lines, Sangamo Therapeutics, and Grayscale Bitcoin Trust Jumped Today Motley Fool +28.96%
04:17PM  Gene-Focused Biotechs Pop After Pfizer Partner Scores In Hemophilia A Investor's Business Daily
12:47PM  Sangamo Soars Amid Multiple Development Pipeline Updates Benzinga
12:43PM  Sangamo Therapeutics Bull Gap Fuels Hot Options Trading Schaeffer's Investment Research
11:53AM  Sangamo Therapeutics News: Why SGMO Stock Is Soaring Today InvestorPlace
11:33AM  Why Sangamo Therapeutics Stock Is Soaring Today Motley Fool
09:55AM  Sangamo Stock Soars on Positive Hemophilia Treatment Trial TheStreet.com
08:10AM  Sangamo's stock soars after upbeat trial data for hemophilia treatment MarketWatch
07:00AM  Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data PR Newswire
07:00AM  Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio PR Newswire
07:00AM  Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy PR Newswire
07:00AM  Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy Business Wire
Apr-01-19 04:43PM  Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update PR Newswire
Mar-29-19 07:00AM  Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology PR Newswire
Mar-28-19 08:19AM  Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
Mar-26-19 07:16AM  Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool
Mar-25-19 09:15AM  S&P Holds Onto 2800 Despite Sharp Selloff Zacks
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yi KathyEVP & Chief Financial OfficerMay 15Option Exercise4.555,00022,75030,512May 17 05:41 PM
Yi KathyEVP & Chief Financial OfficerMay 15Sale10.005,00050,00025,512May 17 05:41 PM
Yi KathyEVP & Chief Financial OfficerApr 15Option Exercise4.555,00022,75030,512Apr 16 07:27 PM
Yi KathyEVP & Chief Financial OfficerApr 15Sale12.115,00060,55025,512Apr 16 07:27 PM
Yi KathyEVP & Chief Financial OfficerMar 15Option Exercise4.555,00022,75030,512Mar 18 07:35 PM
Yi KathyEVP & Chief Financial OfficerMar 15Sale10.005,00050,00025,512Mar 18 07:35 PM
Yi KathyEVP & Chief Financial OfficerMar 01Option Exercise4.555,00022,75030,512Mar 05 08:21 PM
Yi KathyEVP & Chief Financial OfficerMar 01Sale10.005,00050,00025,512Mar 05 08:21 PM
Yi KathySVP & Chief Financial OfficerJan 15Option Exercise4.555,00022,75012,250Jan 16 04:08 PM
Yi KathySVP & Chief Financial OfficerJan 15Sale11.045,00055,2007,250Jan 16 04:08 PM
Conner Edward R.Sr. VP & Chief Medical OfficerJan 07Option Exercise3.205,00016,00017,125Jan 08 05:38 PM
Conner Edward R.Sr. VP & Chief Medical OfficerJan 07Sale12.335,00061,63112,125Jan 08 05:38 PM
Yi KathySVP & Chief Financial OfficerDec 17Option Exercise4.555,00022,75012,250Dec 18 05:35 PM
Yi KathySVP & Chief Financial OfficerDec 17Sale11.445,00057,2007,250Dec 18 05:35 PM